A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma

Cancer

Volumn 79, Issue 2, 1997, Pages 337-344

  Pisansky, Thomas M ^a   Kahn, Michael J ^a   Rasp, Gregory M ^a   Cha, Stephen S ^a   Haddock, Michael G ^a   Bostwick, David G ^a  

^a MAYO CLINIC   (United States)

Author keywords

disease free survival; grade; neoplasm recurrence; prognosis; prostate cancer; prostate specific antigen blood; prostatic neoplasms radiation therapy; radiotherapy; stage; survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; TREATMENT OUTCOME;

HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0031022948     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970115)79:2<337::AID-CNCR17>3.0.CO;2-1     Document Type: Article

References (33)

1. Bagshaw MA, Kaplan ID, Cox RS. Radiation therapy for local-ized disease. Cancer 1993;71:939-52.
2. Swanson GP, Cupps RE, Utz DC, Ilstrup DM, Zincke H, Myers RP. Definitive therapy for prostate carcinoma - Mayo Clinic results at 15 years after treatment. Br J Radial 1994; 67:877-89.
3. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:293-306.
4. Vesalainen S, Nordling S, Lipponen P, Talja M, Syrjanen K. Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy. Br J Cancer 1994;70:309-14.
5. American Joint Committee on Cancer. Manual for staging of cancer. Philadelphia: JB Lippincott, 1992.
6. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Longterm survival among men with conservatively treated localized prostate cancer. JAMA 1995:274:626-31.
7. Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Mohan R, Mageras GS, et al. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 1994:21:580-97.
8. Lieber MM, Murtaugh PA, Farrow GM, Myers RP, Blute ML. DNA ploidy and surgically treated prostate cancer: important independent association with prognosis for patients with prostate carcinoma treated by radical prostatectomy. Cancer 1995;75:1935-43.
9. Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995;45:831-8.
10. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993; 11:2158-66.
11. Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-5.
12. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995;154:456-9.
13. Zagars GK, von Eschenbach AC. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer 1993;72:538-48.
14. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150:110-4.
15. Pisansky TM, Zincke H, Suman VJ, Bostwick DG, Earle JD, Oesterling JE. Correlation of pretherapy prostate cancer characteristics with histologie findings from pelvic lymphad-enectomy specimens. Int J Radiat Oncol Biol Phys 1996; 34:33-9.
16. Pisansky TM, Blute ML, Suman VJ, Bostwick DG, Earle JD, Zincke H. Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys 1996;36:585-91.
17. Gleason DF. Histologic grading of prostatic carcinoma. In: Bostwick DG, editor. Pathology of the prostate. New York: Churchill Livingstone, 1990:83-93.
18. Ferguson JK, Bostwick DG, Suman V, Zincke H, Oesterling JE. Prostate-specific antigen detected prostate cancer -pathological characteristics of ultrasound visible versus ultrasound invisible tumors. Eur Urol 1995;27:8-12.
19. Klee GG, Dodge LA, Zincke H, Oesterling JE. Measurement of serum prostate specific antigen using IMx prostate specific antigen assay. J Urol 1994;151:94-8.
20. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993:270:860-4.
21. Hosmer D, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Denoix PF, Schwanz D. Regeles generales de classification des cancers et de presentation des resultats therapeutics. Acad Chir 1959;85:415-24.
24. Hermanek P, Hutter RV, Sobin LH. Prognostic grouping: the next step in tumor classification. J Cancer Res Clin Oncol 1990;116:513-6.
25. Clemens JD, Feinstein AR, Holabird N, Cartwright S. A new clinical-anatomic staging system for evaluating prognosis and treatment of prostatic cancer. J Chronic Dis 1986; 39:913-28.
26. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, et al. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 1995;55:4114-9.
27. Takahashi S, Alcaraz A, Brown JA, Borell TJ, Herath JF, Bergs-tralh EJ, et al. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pT(3)N(0)M(0)) prostate carcinoma. Clin Cancer Res 1996;2:137-45.
28. Adolfsson J, Steineck G, Whitmore WF. Recent results of management of palpable clinically localized prostate cancer. Cancer 1993;72:310-22.
29. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993;269:2650-8.
30. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" outpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35.
31. Gauwitz MD, Pollack A, el-Naggar AK, Terry NH, von Eschenbach AC, Zagars GK. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 1994; 28:821-8.
32. Song J, Cheng WS, Cupps RE, Earle JD, Farrow GM, Lieber MM. Nuclear deoxyribonucleic acid content measured by static cytometry: important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy. J Urol 1992;147:794-7.
33. Centeno BA, Zietman AL, Shipley WU, Sobczak ML, Shipley JW, Preffer FI, et al. Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 1994;30:309-15.